To our knowledge, we are the first to demonstrate CAP as a potential treatment modality for NF1-associated PNSTs, and our findings are consistent with the findings of others that identify RONS-induced apoptosis as the mechanism by which CAP exerts its anti-cancer effects through the Caspase 3 pathway. Here, CASP3 is linked to cancer.